Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Next-generation sequencing (NGS) technology, which has been used at Illumina since 2007, builds upon earlier genome sequencing methods to greatly reduce the time taken to sequence DNA. When the ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...

Illumina shares tumbled 8% Friday on investor concerns about the future of the gene-sequencing equipment maker’s business in ...

Gene sequencing machine maker Illumina forecast 2025 revenue largely below Wall Street estimates on Thursday, signaling ...

Illumina is one of Mainboard-listed Venture Corporation’s major customers. Illumina’s shares have fallen some 26.4% over the ...

The advent of next-generation sequencing has made possible genome analysis at previously unattainable depth. Roche, Illumina and Life Technologies, among others, have developed well-established ...

TD Cowen downgraded Illumina (ILMN) to Hold from Buy with a price target of $140, down from $177. Accelerating high throughput next-generation ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Genomics company Illumina (NASDAQ:ILMN) reported Q4 CY2024 results , but sales were flat year on year at $1.1 billion. On the ...

SAN DIEGO, Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...